Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.41 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.41 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.41 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.41 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.41 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL839163 | 1.00 | ALDH1A1 (0.56) | ALDH1A1ALOX15GRM1TSHRSMN1; SMN2 | |
| SCHEMBL25283997 | 0.92 | GRM1 (0.55) | ALDH1A1ALOX15GRM1TSHRSMN1; SMN2 | |
| SCHEMBL25283998 | 0.92 | GRM1 (0.55) | ALDH1A1ALOX15GRM1TSHRSMN1; SMN2 | |
| SCHEMBL28310834 | 0.81 | ALDH1A1 (0.53) | ALDH1A1ALOX15GRM1TSHRSMN1; SMN2 | |
| SCHEMBL24520263 | 0.80 | ALDH1A1 (0.42) | ALDH1A1ALOX15GRM1TSHRSMN1; SMN2 | |
| SCHEMBL22133058 | 0.78 | ALDH1A1 (0.51) | ALDH1A1ALOX15TSHRSMN1; SMN2NPSR1 | |
| SCHEMBL14086753 | 0.78 | SMN1; SMN2 (0.46) | ALDH1A1ALOX15TSHRSMN1; SMN2NPSR1 | |
| Carbamic Acid SCHEMBL27703082 | 0.77 | ALDH1A1 (0.47) | ALDH1A1ALOX15TSHRSMN1; SMN2NPSR1 | |
| SCHEMBL22117545 | 0.76 | GRM1 (0.52) | ALDH1A1ALOX15GRM1GRIN2DGRIN3B | |
| SCHEMBL22117543 | 0.76 | GRM1 (0.52) | ALDH1A1ALOX15GRM1GRIN2DGRIN3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020187934-A1 | Peptide derivatives | SYNGENTA LIMITED (GB) | 2002-12-12 | — | — | US | claimed |
| US-6355617-B1 | PEPTIDES, HYDROPHOBIC RESIDUES, AMINO ACIDS AND SEQUENCE | SYNGENTA LIMITED (GB) | 2002-03-12 | — | — | US | claimed |
| EP-0882066-B1 | PEPTIDE DERIVATIVES | ZENECA LTD (GB) | 2000-09-06 | — | — | EP | claimed |
| US-12404300-B2 | Mitochondria-targeting peptides | STEALTH BIOTHERAPEUTICS INC. (US) | 2025-09-02 | — | — | US | disclosed |
| CN-113544138-B | Mitochondrial targeting peptides | 隐形生物治疗公司 | 2024-10-29 | — | — | CN | disclosed |
| US-20230279052-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2023-09-07 | — | — | US | disclosed |
| US-20230279052-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | STEALTH BIOTHERAPEUTICS INC. | 2023-09-07 | — | — | US | disclosed |
| CN-114302741-A | Compositions and methods for treating autoimmune disorders | 密执安大学评议会 | 2022-04-08 | — | — | CN | disclosed |
| EP-3898652-A1 | MITOCHONDRIA-TARGETING PEPTIDES | Stealth Biotherapeutics Corp (MC) | 2021-10-27 | — | — | EP | disclosed |
| CN-113544138-A | Mitochondrial targeting peptides | 隐形生物治疗公司 | 2021-10-22 | — | — | CN | disclosed |
| WO-2020131282-A1 | MITOCHONDRIA-TARGETING PEPTIDES | STEALTH BIOTHERAPEUTICS CORP. (MC) | 2020-06-25 | — | — | WO | disclosed |
| EP-0286813-A2 | Renin-inhibiting amino acid derivatives | MERCK PATENT GmbH (DE) | 1988-10-19 | — | — | EP | disclosed |
| EP-0049628-B1 | NONAPEPTIDE AND DECAPEPTIDE ANALOGS OF LHRH, USEFUL AS LHRH ANTAGONISTS, METHODS OF MAKING THEM, AND THEIR PHARMACEUTICAL USES | SYNTEX (U.S.A.) INC. (US) | 1985-07-03 | — | — | EP | disclosed |
| EP-0021234-B1 | NONAPEPTIDE AND DECAPEPTIDE DERIVATIVES OF LUTEINIZING HORMONE RELEASING HORMONE, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SYNTEX (U.S.A.) INC. (US) | 1984-08-22 | — | — | EP | disclosed |
| US-4419347-A | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists | SYNTEX (U.S.A.) INC. (US) | 1983-12-06 | — | — | US | disclosed |
| US-4341767-A | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists | SYNTEX INC. (US) | 1982-07-27 | — | — | US | disclosed |
| EP-0049628-A2 | Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists, methods of making them, and their pharmaceutical uses | SYNTEX (U.S.A.) INC. (US) | 1982-04-14 | — | — | EP | disclosed |
| US-4273704-A | N-Adamantane-substituted tetrapeptide amides | G. D. SEARLE & CO. (US) | 1981-06-16 | — | — | US | disclosed |
| EP-0021234-A1 | Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone, their preparation and pharmaceutical compositions containing them | SYNTEX (U.S.A.) INC. (US) | 1981-01-07 | — | — | EP | disclosed |
| US-4234571-A | CONTRACEPTIVES, ANTIFERTILITY AGENTS | SYNTEX (U.S.A.) INC. (US) | 1980-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279052-A1 | PRODRUGS OF MITOCHONDRIA-TARGETING OLIGOPEPTIDES | ARG2, NLN, OAT | ALDH1A1 4412/4885ALOX15 4339/4885GRM1 2376/4885 |
| US-20020187934-A1 | Peptide derivatives | HLA-DRB1, MICA, TAP1 | ALDH1A1 3162/4885ALOX15 4065/4885GRM1 1364/4885 |
| US-12404300-B2 | Mitochondria-targeting peptides | SSBP1, HSPE1, IMMT | ALDH1A1 3271/4885ALOX15 2774/4885GRM1 3611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.